Synthesis, characterization, and assessment of cytotoxic properties of a series of titanocene dichloride derivatives

Organometallics

Volumn 23, Issue 19, 2004, Pages 4486-4494

  Causey, Patrick W ^a   Baird, Michael C ^a   Cole, Susan P C ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC COMPOUNDS; CATALYSTS; COMPOSITION; CORRELATION METHODS; CRYSTALLOGRAPHY; CYTOLOGY; DRUG DOSAGE; ESTERS; POSITIVE IONS; PULMONARY DISEASES; SPECTROMETERS; SYNTHESIS (CHEMICAL); TITANIUM COMPOUNDS; TUMORS;

ANTICANCER DRUGS; CISPLATIN; CYTOTOXICITY; TITANOCENE DICHLORIDE DERIVATIVES;

ORGANOMETALLICS;

EID: 4544314578     PISSN: 02767333     EISSN: None     Source Type: Journal    
DOI: 10.1021/om049679w     Document Type: Review

References (53)

1. (a) Rosenberg, B.; Van Camp, L.; Trosko, J. E.; Mansour, V. H. Nature (London) 1969, 222, 385.
2. For recent reviews, see: (b) Reedijk, J. Chem. Commun. 1996, 801. (c) Sharma, V.; Piwnica-Worms, D. Chem. Rev. 1999, 99, 2545. (d) Natile, G.; Coluocia, M. Coord. Chem. Rev. 2001, 216-217, 383. (e) Wheate, N. J.; Collins, J. G. Coord. Chem. Rev. 2003, 241, 133. (f) Fuertes, M. A.; Alonso, C.; Pérez, J. M. Chem. Rev. 2003, 103, 645.
3. For recent reviews, see: (b) Reedijk, J. Chem. Commun. 1996, 801. (c) Sharma, V.; Piwnica-Worms, D. Chem. Rev. 1999, 99, 2545. (d) Natile, G.; Coluocia, M. Coord. Chem. Rev. 2001, 216-217, 383. (e) Wheate, N. J.; Collins, J. G. Coord. Chem. Rev. 2003, 241, 133. (f) Fuertes, M. A.; Alonso, C.; Pérez, J. M. Chem. Rev. 2003, 103, 645.
4. For recent reviews, see: (b) Reedijk, J. Chem. Commun. 1996, 801. (c) Sharma, V.; Piwnica-Worms, D. Chem. Rev. 1999, 99, 2545. (d) Natile, G.; Coluocia, M. Coord. Chem. Rev. 2001, 216-217, 383. (e) Wheate, N. J.; Collins, J. G. Coord. Chem. Rev. 2003, 241, 133. (f) Fuertes, M. A.; Alonso, C.; Pérez, J. M. Chem. Rev. 2003, 103, 645.
5. For recent reviews, see: (b) Reedijk, J. Chem. Commun. 1996, 801. (c) Sharma, V.; Piwnica-Worms, D. Chem. Rev. 1999, 99, 2545. (d) Natile, G.; Coluocia, M. Coord. Chem. Rev. 2001, 216-217, 383. (e) Wheate, N. J.; Collins, J. G. Coord. Chem. Rev. 2003, 241, 133. (f) Fuertes, M. A.; Alonso, C.; Pérez, J. M. Chem. Rev. 2003, 103, 645.
6. For recent reviews, see: (b) Reedijk, J. Chem. Commun. 1996, 801. (c) Sharma, V.; Piwnica-Worms, D. Chem. Rev. 1999, 99, 2545. (d) Natile, G.; Coluocia, M. Coord. Chem. Rev. 2001, 216-217, 383. (e) Wheate, N. J.; Collins, J. G. Coord. Chem. Rev. 2003, 241, 133. (f) Fuertes, M. A.; Alonso, C.; Pérez, J. M. Chem. Rev. 2003, 103, 645.
7. For reviews, see: (a) Clarke, M. J., Zhu, F.; Frasca, D. R. Chem. Rev. 1999, 99, 2511. (b) Köpf-Maier, P.; Köpf, H. Chem. Rev. 1987, 87, 1137. (c) Köpf-Maier, P.; Köpf, H. Struct. Bonding 1988, 70, 103. For recent work, see: (d) Fairlie, D. P.; Whitehouse, M. W.; Broomhead, J. A. Chem.-Biol. Interact. 1987, 61, 277. (e) Harstrick, A.; Schmoll, H. J.; Saas, G.; Poliwoda, H.; Rustum, Y. Eur. J. Cancer 1993, 29A, 1000. (f) Kröger, N.; Kleeberg, U. R.; Mross, K.; Edler, L.; Sass, G.; Hossfeld, D. K. Onkologie 2000, 23, 60. (g) Tarillion, P.; Taubert, G.; Nenning, H. Mutat. Res. 1997, 389, 213. (h) Villena-Heinsen, C.; Friedrich, M.; Ertan, A. K.; Farnhammer, C.; Schmidt, W. Anticancer Drugs 1998, 9, 557. (i) Christodoulou, C. V.; Eliopoulos, A. G.; Young, L. S.; Hodgkins, L.; Ferry, D. H.; Kerr, D. J. Br. J. Cancer 1998, 77, 2088. (j) Valadares, M. C.; Klein, S. L; Zyngier, S.; Queiroz, M. L. S. Int. J. Immunopharm. 1998, 20, 573. (k) Kopf-Maier, P. Anticancer Res. 1999, 19, 493. (l) Ghosh P.; D'Cruz, O. J.; Narla, R. K.; Uckun, F. M. Clin. Cancer Res. 2000, 6, 1536. (m) Mokdsi, G.; Harding, M. M. J. Inorg. Biochem. 2001, 83, 205.
8. For reviews, see: (a) Clarke, M. J., Zhu, F.; Frasca, D. R. Chem. Rev. 1999, 99, 2511. (b) Köpf-Maier, P.; Köpf, H. Chem. Rev. 1987, 87, 1137. (c) Köpf-Maier, P.; Köpf, H. Struct. Bonding 1988, 70, 103. For recent work, see: (d) Fairlie, D. P.; Whitehouse, M. W.; Broomhead, J. A. Chem.-Biol. Interact. 1987, 61, 277. (e) Harstrick, A.; Schmoll, H. J.; Saas, G.; Poliwoda, H.; Rustum, Y. Eur. J. Cancer 1993, 29A, 1000. (f) Kröger, N.; Kleeberg, U. R.; Mross, K.; Edler, L.; Sass, G.; Hossfeld, D. K. Onkologie 2000, 23, 60. (g) Tarillion, P.; Taubert, G.; Nenning, H. Mutat. Res. 1997, 389, 213. (h) Villena-Heinsen, C.; Friedrich, M.; Ertan, A. K.; Farnhammer, C.; Schmidt, W. Anticancer Drugs 1998, 9, 557. (i) Christodoulou, C. V.; Eliopoulos, A. G.; Young, L. S.; Hodgkins, L.; Ferry, D. H.; Kerr, D. J. Br. J. Cancer 1998, 77, 2088. (j) Valadares, M. C.; Klein, S. L; Zyngier, S.; Queiroz, M. L. S. Int. J. Immunopharm. 1998, 20, 573. (k) Kopf-Maier, P. Anticancer Res. 1999, 19, 493. (l) Ghosh P.; D'Cruz, O. J.; Narla, R. K.; Uckun, F. M. Clin. Cancer Res. 2000, 6, 1536. (m) Mokdsi, G.; Harding, M. M. J. Inorg. Biochem. 2001, 83, 205.
9. For reviews, see: (a) Clarke, M. J., Zhu, F.; Frasca, D. R. Chem. Rev. 1999, 99, 2511. (b) Köpf-Maier, P.; Köpf, H. Chem. Rev. 1987, 87, 1137. (c) Köpf-Maier, P.; Köpf, H. Struct. Bonding 1988, 70, 103. For recent work, see: (d) Fairlie, D. P.; Whitehouse, M. W.; Broomhead, J. A. Chem.-Biol. Interact. 1987, 61, 277. (e) Harstrick, A.; Schmoll, H. J.; Saas, G.; Poliwoda, H.; Rustum, Y. Eur. J. Cancer 1993, 29A, 1000. (f) Kröger, N.; Kleeberg, U. R.; Mross, K.; Edler, L.; Sass, G.; Hossfeld, D. K. Onkologie 2000, 23, 60. (g) Tarillion, P.; Taubert, G.; Nenning, H. Mutat. Res. 1997, 389, 213. (h) Villena-Heinsen, C.; Friedrich, M.; Ertan, A. K.; Farnhammer, C.; Schmidt, W. Anticancer Drugs 1998, 9, 557. (i) Christodoulou, C. V.; Eliopoulos, A. G.; Young, L. S.; Hodgkins, L.; Ferry, D. H.; Kerr, D. J. Br. J. Cancer 1998, 77, 2088. (j) Valadares, M. C.; Klein, S. L; Zyngier, S.; Queiroz, M. L. S. Int. J. Immunopharm. 1998, 20, 573. (k) Kopf-Maier, P. Anticancer Res. 1999, 19, 493. (l) Ghosh P.; D'Cruz, O. J.; Narla, R. K.; Uckun, F. M. Clin. Cancer Res. 2000, 6, 1536. (m) Mokdsi, G.; Harding, M. M. J. Inorg. Biochem. 2001, 83, 205.
10. For reviews, see: (a) Clarke, M. J., Zhu, F.; Frasca, D. R. Chem. Rev. 1999, 99, 2511. (b) Köpf-Maier, P.; Köpf, H. Chem. Rev. 1987, 87, 1137. (c) Köpf-Maier, P.; Köpf, H. Struct. Bonding 1988, 70, 103. For recent work, see: (d) Fairlie, D. P.; Whitehouse, M. W.; Broomhead, J. A. Chem.-Biol. Interact. 1987, 61, 277. (e) Harstrick, A.; Schmoll, H. J.; Saas, G.; Poliwoda, H.; Rustum, Y. Eur. J. Cancer 1993, 29A, 1000. (f) Kröger, N.; Kleeberg, U. R.; Mross, K.; Edler, L.; Sass, G.; Hossfeld, D. K. Onkologie 2000, 23, 60. (g) Tarillion, P.; Taubert, G.; Nenning, H. Mutat. Res. 1997, 389, 213. (h) Villena-Heinsen, C.; Friedrich, M.; Ertan, A. K.; Farnhammer, C.; Schmidt, W. Anticancer Drugs 1998, 9, 557. (i) Christodoulou, C. V.; Eliopoulos, A. G.; Young, L. S.; Hodgkins, L.; Ferry, D. H.; Kerr, D. J. Br. J. Cancer 1998, 77, 2088. (j) Valadares, M. C.; Klein, S. L; Zyngier, S.; Queiroz, M. L. S. Int. J. Immunopharm. 1998, 20, 573. (k) Kopf-Maier, P. Anticancer Res. 1999, 19, 493. (l) Ghosh P.; D'Cruz, O. J.; Narla, R. K.; Uckun, F. M. Clin. Cancer Res. 2000, 6, 1536. (m) Mokdsi, G.; Harding, M. M. J. Inorg. Biochem. 2001, 83, 205.
11. For reviews, see: (a) Clarke, M. J., Zhu, F.; Frasca, D. R. Chem. Rev. 1999, 99, 2511. (b) Köpf-Maier, P.; Köpf, H. Chem. Rev. 1987, 87, 1137. (c) Köpf-Maier, P.; Köpf, H. Struct. Bonding 1988, 70, 103. For recent work, see: (d) Fairlie, D. P.; Whitehouse, M. W.; Broomhead, J. A. Chem.-Biol. Interact. 1987, 61, 277. (e) Harstrick, A.; Schmoll, H. J.; Saas, G.; Poliwoda, H.; Rustum, Y. Eur. J. Cancer 1993, 29A, 1000. (f) Kröger, N.; Kleeberg, U. R.; Mross, K.; Edler, L.; Sass, G.; Hossfeld, D. K. Onkologie 2000, 23, 60. (g) Tarillion, P.; Taubert, G.; Nenning, H. Mutat. Res. 1997, 389, 213. (h) Villena-Heinsen, C.; Friedrich, M.; Ertan, A. K.; Farnhammer, C.; Schmidt, W. Anticancer Drugs 1998, 9, 557. (i) Christodoulou, C. V.; Eliopoulos, A. G.; Young, L. S.; Hodgkins, L.; Ferry, D. H.; Kerr, D. J. Br. J. Cancer 1998, 77, 2088. (j) Valadares, M. C.; Klein, S. L; Zyngier, S.; Queiroz, M. L. S. Int. J. Immunopharm. 1998, 20, 573. (k) Kopf-Maier, P. Anticancer Res. 1999, 19, 493. (l) Ghosh P.; D'Cruz, O. J.; Narla, R. K.; Uckun, F. M. Clin. Cancer Res. 2000, 6, 1536. (m) Mokdsi, G.; Harding, M. M. J. Inorg. Biochem. 2001, 83, 205.
12. For reviews, see: (a) Clarke, M. J., Zhu, F.; Frasca, D. R. Chem. Rev. 1999, 99, 2511. (b) Köpf-Maier, P.; Köpf, H. Chem. Rev. 1987, 87, 1137. (c) Köpf-Maier, P.; Köpf, H. Struct. Bonding 1988, 70, 103. For recent work, see: (d) Fairlie, D. P.; Whitehouse, M. W.; Broomhead, J. A. Chem.-Biol. Interact. 1987, 61, 277. (e) Harstrick, A.; Schmoll, H. J.; Saas, G.; Poliwoda, H.; Rustum, Y. Eur. J. Cancer 1993, 29A, 1000. (f) Kröger, N.; Kleeberg, U. R.; Mross, K.; Edler, L.; Sass, G.; Hossfeld, D. K. Onkologie 2000, 23, 60. (g) Tarillion, P.; Taubert, G.; Nenning, H. Mutat. Res. 1997, 389, 213. (h) Villena-Heinsen, C.; Friedrich, M.; Ertan, A. K.; Farnhammer, C.; Schmidt, W. Anticancer Drugs 1998, 9, 557. (i) Christodoulou, C. V.; Eliopoulos, A. G.; Young, L. S.; Hodgkins, L.; Ferry, D. H.; Kerr, D. J. Br. J. Cancer 1998, 77, 2088. (j) Valadares, M. C.; Klein, S. L; Zyngier, S.; Queiroz, M. L. S. Int. J. Immunopharm. 1998, 20, 573. (k) Kopf-Maier, P. Anticancer Res. 1999, 19, 493. (l) Ghosh P.; D'Cruz, O. J.; Narla, R. K.; Uckun, F. M. Clin. Cancer Res. 2000, 6, 1536. (m) Mokdsi, G.; Harding, M. M. J. Inorg. Biochem. 2001, 83, 205.
13. For reviews, see: (a) Clarke, M. J., Zhu, F.; Frasca, D. R. Chem. Rev. 1999, 99, 2511. (b) Köpf-Maier, P.; Köpf, H. Chem. Rev. 1987, 87, 1137. (c) Köpf-Maier, P.; Köpf, H. Struct. Bonding 1988, 70, 103. For recent work, see: (d) Fairlie, D. P.; Whitehouse, M. W.; Broomhead, J. A. Chem.-Biol. Interact. 1987, 61, 277. (e) Harstrick, A.; Schmoll, H. J.; Saas, G.; Poliwoda, H.; Rustum, Y. Eur. J. Cancer 1993, 29A, 1000. (f) Kröger, N.; Kleeberg, U. R.; Mross, K.; Edler, L.; Sass, G.; Hossfeld, D. K. Onkologie 2000, 23, 60. (g) Tarillion, P.; Taubert, G.; Nenning, H. Mutat. Res. 1997, 389, 213. (h) Villena-Heinsen, C.; Friedrich, M.; Ertan, A. K.; Farnhammer, C.; Schmidt, W. Anticancer Drugs 1998, 9, 557. (i) Christodoulou, C. V.; Eliopoulos, A. G.; Young, L. S.; Hodgkins, L.; Ferry, D. H.; Kerr, D. J. Br. J. Cancer 1998, 77, 2088. (j) Valadares, M. C.; Klein, S. L; Zyngier, S.; Queiroz, M. L. S. Int. J. Immunopharm. 1998, 20, 573. (k) Kopf-Maier, P. Anticancer Res. 1999, 19, 493. (l) Ghosh P.; D'Cruz, O. J.; Narla, R. K.; Uckun, F. M. Clin. Cancer Res. 2000, 6, 1536. (m) Mokdsi, G.; Harding, M. M. J. Inorg. Biochem. 2001, 83, 205.
14. For reviews, see: (a) Clarke, M. J., Zhu, F.; Frasca, D. R. Chem. Rev. 1999, 99, 2511. (b) Köpf-Maier, P.; Köpf, H. Chem. Rev. 1987, 87, 1137. (c) Köpf-Maier, P.; Köpf, H. Struct. Bonding 1988, 70, 103. For recent work, see: (d) Fairlie, D. P.; Whitehouse, M. W.; Broomhead, J. A. Chem.-Biol. Interact. 1987, 61, 277. (e) Harstrick, A.; Schmoll, H. J.; Saas, G.; Poliwoda, H.; Rustum, Y. Eur. J. Cancer 1993, 29A, 1000. (f) Kröger, N.; Kleeberg, U. R.; Mross, K.; Edler, L.; Sass, G.; Hossfeld, D. K. Onkologie 2000, 23, 60. (g) Tarillion, P.; Taubert, G.; Nenning, H. Mutat. Res. 1997, 389, 213. (h) Villena-Heinsen, C.; Friedrich, M.; Ertan, A. K.; Farnhammer, C.; Schmidt, W. Anticancer Drugs 1998, 9, 557. (i) Christodoulou, C. V.; Eliopoulos, A. G.; Young, L. S.; Hodgkins, L.; Ferry, D. H.; Kerr, D. J. Br. J. Cancer 1998, 77, 2088. (j) Valadares, M. C.; Klein, S. L; Zyngier, S.; Queiroz, M. L. S. Int. J. Immunopharm. 1998, 20, 573. (k) Kopf-Maier, P. Anticancer Res. 1999, 19, 493. (l) Ghosh P.; D'Cruz, O. J.; Narla, R. K.; Uckun, F. M. Clin. Cancer Res. 2000, 6, 1536. (m) Mokdsi, G.; Harding, M. M. J. Inorg. Biochem. 2001, 83, 205.
15. For reviews, see: (a) Clarke, M. J., Zhu, F.; Frasca, D. R. Chem. Rev. 1999, 99, 2511. (b) Köpf-Maier, P.; Köpf, H. Chem. Rev. 1987, 87, 1137. (c) Köpf-Maier, P.; Köpf, H. Struct. Bonding 1988, 70, 103. For recent work, see: (d) Fairlie, D. P.; Whitehouse, M. W.; Broomhead, J. A. Chem.-Biol. Interact. 1987, 61, 277. (e) Harstrick, A.; Schmoll, H. J.; Saas, G.; Poliwoda, H.; Rustum, Y. Eur. J. Cancer 1993, 29A, 1000. (f) Kröger, N.; Kleeberg, U. R.; Mross, K.; Edler, L.; Sass, G.; Hossfeld, D. K. Onkologie 2000, 23, 60. (g) Tarillion, P.; Taubert, G.; Nenning, H. Mutat. Res. 1997, 389, 213. (h) Villena-Heinsen, C.; Friedrich, M.; Ertan, A. K.; Farnhammer, C.; Schmidt, W. Anticancer Drugs 1998, 9, 557. (i) Christodoulou, C. V.; Eliopoulos, A. G.; Young, L. S.; Hodgkins, L.; Ferry, D. H.; Kerr, D. J. Br. J. Cancer 1998, 77, 2088. (j) Valadares, M. C.; Klein, S. L; Zyngier, S.; Queiroz, M. L. S. Int. J. Immunopharm. 1998, 20, 573. (k) Kopf-Maier, P. Anticancer Res. 1999, 19, 493. (l) Ghosh P.; D'Cruz, O. J.; Narla, R. K.; Uckun, F. M. Clin. Cancer Res. 2000, 6, 1536. (m) Mokdsi, G.; Harding, M. M. J. Inorg. Biochem. 2001, 83, 205.
16. For reviews, see: (a) Clarke, M. J., Zhu, F.; Frasca, D. R. Chem. Rev. 1999, 99, 2511. (b) Köpf-Maier, P.; Köpf, H. Chem. Rev. 1987, 87, 1137. (c) Köpf-Maier, P.; Köpf, H. Struct. Bonding 1988, 70, 103. For recent work, see: (d) Fairlie, D. P.; Whitehouse, M. W.; Broomhead, J. A. Chem.-Biol. Interact. 1987, 61, 277. (e) Harstrick, A.; Schmoll, H. J.; Saas, G.; Poliwoda, H.; Rustum, Y. Eur. J. Cancer 1993, 29A, 1000. (f) Kröger, N.; Kleeberg, U. R.; Mross, K.; Edler, L.; Sass, G.; Hossfeld, D. K. Onkologie 2000, 23, 60. (g) Tarillion, P.; Taubert, G.; Nenning, H. Mutat. Res. 1997, 389, 213. (h) Villena-Heinsen, C.; Friedrich, M.; Ertan, A. K.; Farnhammer, C.; Schmidt, W. Anticancer Drugs 1998, 9, 557. (i) Christodoulou, C. V.; Eliopoulos, A. G.; Young, L. S.; Hodgkins, L.; Ferry, D. H.; Kerr, D. J. Br. J. Cancer 1998, 77, 2088. (j) Valadares, M. C.; Klein, S. L; Zyngier, S.; Queiroz, M. L. S. Int. J. Immunopharm. 1998, 20, 573. (k) Kopf-Maier, P. Anticancer Res. 1999, 19, 493. (l) Ghosh P.; D'Cruz, O. J.; Narla, R. K.; Uckun, F. M. Clin. Cancer Res. 2000, 6, 1536. (m) Mokdsi, G.; Harding, M. M. J. Inorg. Biochem. 2001, 83, 205.
17. For reviews, see: (a) Clarke, M. J., Zhu, F.; Frasca, D. R. Chem. Rev. 1999, 99, 2511. (b) Köpf-Maier, P.; Köpf, H. Chem. Rev. 1987, 87, 1137. (c) Köpf-Maier, P.; Köpf, H. Struct. Bonding 1988, 70, 103. For recent work, see: (d) Fairlie, D. P.; Whitehouse, M. W.; Broomhead, J. A. Chem.-Biol. Interact. 1987, 61, 277. (e) Harstrick, A.; Schmoll, H. J.; Saas, G.; Poliwoda, H.; Rustum, Y. Eur. J. Cancer 1993, 29A, 1000. (f) Kröger, N.; Kleeberg, U. R.; Mross, K.; Edler, L.; Sass, G.; Hossfeld, D. K. Onkologie 2000, 23, 60. (g) Tarillion, P.; Taubert, G.; Nenning, H. Mutat. Res. 1997, 389, 213. (h) Villena-Heinsen, C.; Friedrich, M.; Ertan, A. K.; Farnhammer, C.; Schmidt, W. Anticancer Drugs 1998, 9, 557. (i) Christodoulou, C. V.; Eliopoulos, A. G.; Young, L. S.; Hodgkins, L.; Ferry, D. H.; Kerr, D. J. Br. J. Cancer 1998, 77, 2088. (j) Valadares, M. C.; Klein, S. L; Zyngier, S.; Queiroz, M. L. S. Int. J. Immunopharm. 1998, 20, 573. (k) Kopf-Maier, P. Anticancer Res. 1999, 19, 493. (l) Ghosh P.; D'Cruz, O. J.; Narla, R. K.; Uckun, F. M. Clin. Cancer Res. 2000, 6, 1536. (m) Mokdsi, G.; Harding, M. M. J. Inorg. Biochem. 2001, 83, 205.
18. For reviews, see: (a) Clarke, M. J., Zhu, F.; Frasca, D. R. Chem. Rev. 1999, 99, 2511. (b) Köpf-Maier, P.; Köpf, H. Chem. Rev. 1987, 87, 1137. (c) Köpf-Maier, P.; Köpf, H. Struct. Bonding 1988, 70, 103. For recent work, see: (d) Fairlie, D. P.; Whitehouse, M. W.; Broomhead, J. A. Chem.-Biol. Interact. 1987, 61, 277. (e) Harstrick, A.; Schmoll, H. J.; Saas, G.; Poliwoda, H.; Rustum, Y. Eur. J. Cancer 1993, 29A, 1000. (f) Kröger, N.; Kleeberg, U. R.; Mross, K.; Edler, L.; Sass, G.; Hossfeld, D. K. Onkologie 2000, 23, 60. (g) Tarillion, P.; Taubert, G.; Nenning, H. Mutat. Res. 1997, 389, 213. (h) Villena-Heinsen, C.; Friedrich, M.; Ertan, A. K.; Farnhammer, C.; Schmidt, W. Anticancer Drugs 1998, 9, 557. (i) Christodoulou, C. V.; Eliopoulos, A. G.; Young, L. S.; Hodgkins, L.; Ferry, D. H.; Kerr, D. J. Br. J. Cancer 1998, 77, 2088. (j) Valadares, M. C.; Klein, S. L; Zyngier, S.; Queiroz, M. L. S. Int. J. Immunopharm. 1998, 20, 573. (k) Kopf-Maier, P. Anticancer Res. 1999, 19, 493. (l) Ghosh P.; D'Cruz, O. J.; Narla, R. K.; Uckun, F. M. Clin. Cancer Res. 2000, 6, 1536. (m) Mokdsi, G.; Harding, M. M. J. Inorg. Biochem. 2001, 83, 205.
19. For reviews, see: (a) Clarke, M. J., Zhu, F.; Frasca, D. R. Chem. Rev. 1999, 99, 2511. (b) Köpf-Maier, P.; Köpf, H. Chem. Rev. 1987, 87, 1137. (c) Köpf-Maier, P.; Köpf, H. Struct. Bonding 1988, 70, 103. For recent work, see: (d) Fairlie, D. P.; Whitehouse, M. W.; Broomhead, J. A. Chem.-Biol. Interact. 1987, 61, 277. (e) Harstrick, A.; Schmoll, H. J.; Saas, G.; Poliwoda, H.; Rustum, Y. Eur. J. Cancer 1993, 29A, 1000. (f) Kröger, N.; Kleeberg, U. R.; Mross, K.; Edler, L.; Sass, G.; Hossfeld, D. K. Onkologie 2000, 23, 60. (g) Tarillion, P.; Taubert, G.; Nenning, H. Mutat. Res. 1997, 389, 213. (h) Villena-Heinsen, C.; Friedrich, M.; Ertan, A. K.; Farnhammer, C.; Schmidt, W. Anticancer Drugs 1998, 9, 557. (i) Christodoulou, C. V.; Eliopoulos, A. G.; Young, L. S.; Hodgkins, L.; Ferry, D. H.; Kerr, D. J. Br. J. Cancer 1998, 77, 2088. (j) Valadares, M. C.; Klein, S. L; Zyngier, S.; Queiroz, M. L. S. Int. J. Immunopharm. 1998, 20, 573. (k) Kopf-Maier, P. Anticancer Res. 1999, 19, 493. (l) Ghosh P.; D'Cruz, O. J.; Narla, R. K.; Uckun, F. M. Clin. Cancer Res. 2000, 6, 1536. (m) Mokdsi, G.; Harding, M. M. J. Inorg. Biochem. 2001, 83, 205.
20. (a) Köpf-Maier, P. Eur. J. Clin. Pharm. 1994, 47, 1.
21. (b) Yang, P.; Guo, M. Coord. Chem. Rev. 1999, 185-186 189.
22. (c) Harding, M. M.; Mokdsi, G. Curr. Med. Chem. 2000, 7, 1289.
23. (d) Guo, M.; Sun, H.; Bihari, S.; Parkinson, J. A.; Gould, R. O.; Parsons, S.; Sadler, P. J. Inorg. Chem. 2000, 39, 206.
24. (e) Guo, M.; Sun, H.; McArdle, H. J.; Gambling, L.; Sadler, P. J. Biochemistry 2000, 39, 10023.
25. (f) Guo, M.; Guo, Z.; Sadler, P. J. J. Biol. Inorg. Chem. 2001, 6, 698.
26. (g) Moebus, V. J.; Stein, R.; Kieback, D. G.; Runnebaum, I. B.; Sass, G. ; Kreienberb, R. Anticancer Res. 1997, 17, 815.
27. (a) Toney, J. H.; Marks, T. J. J. Am. Chem. Soc. 1985, 107, 947.
28. (b) Mokdsi, G.; Harding, M. M. J. Organomet. Chem. 1998, 565, 29.
29. (a) Boyles, J. R.; Baird, M. C.; Campling, B. G.; Jain, N. J. Inorg. Biochem. 2001, 84, 159.
30. (b) Causey, P. W.; Sparks, K.; Cole, S. P. C.; Baird, M. C., unpublished results.
31. (a) Muller, B. W.; Muller, R.; Lucks, S.; Mohr, W. (Medac Gesellschaft fur Klinische Spezialpraparate mbH, Hamburg) US Patent 5,296,237, 1994.
32. (b) Kurbacher, C. M.; Nagel, W.; Mallmann, P.; Kurbacher, J. A.; Sass, G.; Huebner, H.; Andreotti, P. E.; Krebs, D. Anticancer Res. 1994, 14, 1529.
33. (c) Kurbacher, C. M.; Bruckner, H. W.; Andreotti, P. E.; Kurbacher, J. A.; Sass, G.; Krebs, D. Anti-Cancer Drugs 1995, 6, 697.
34. (d) Luemmen, G.; Sperling, H.; Luboldt, H.; Otto, T.; Ruebben, H. Cancer Chemother. Pharmacol. 1998, 42, 415.
35. (e) Christodoulou, C. V.; Ferry, D. R.; Fyfe, D. W.; Young, A.; Doran, J.; Sheehan, T. M. T.; Eliopoulos, A.; Hale, K.; Baumgart, J.; Sass, G.; Kerr, D. J. J. Clin. Oncol. 1998, 16, 2761.
36. (f) Korfel, A.; Scheulen, M. E.; Schmoll, H.-J.; Grundel, O.; Harstrick, A.; Knoche, M.; Fels, L. M.; Skorzec, M.; Bach, F.; Baumgart, J.; Sass, G.; Seeber, S.; Thiel, E.; Berdel, W. E. Clinical Cancer Res. 1998, 4, 2701.
37. (g) Wittrisch, H.; Schroeer, H.-P.; Vogt, J.; Vogt, C. Electrophoresis 1998, 19, 3012.
38. (a) Jutzi, P.; Redeker, T.; Neumann, B.; Stammler, H. G. Organometallics 1996, 15, 4153.
39. (b) Jutzi, P.; Redeker, T.; Neumann, B.; Stammler, H.-G. Chem. Ber. 1996, 129, 1509.
40. (c) Enders, M.; Köhler, K.; Frosch, W.; Pritzkow, H.; Lang, H. J. Organomet. Chem. 1997, 538, 163.
41. (d) McGowan, M. A. D.; McGowan, P. C. Inorg, Chem. Commun. 2000, 3, 337.
42. (e) Hitchcock, P. B.; Leigh, G. J.; Togrou, M. J. Organomet. Chem. 2003, 669, 101.
43. Allen, O. R.; Croll, L.; Gott, A. L.; Knox, R. J.; McGowan, P. C. Organometallics 2004, 23, 288.
44. Campling, B. G.; Pym, J.; Baker, H. M.; Cole, S. P. C.; Lam, Y. M. Br. J. Cancer 1991, 63, 75.
45. (a) SHELXTL NT: Crystal Structure Analysis Package, version 5.10; Bruker AXS Inc.: Madison, WI, 1999.
46. (b) Cromer, D. T.; Waber, J. T. International Tables for X-ray Crystallography; Kynoch Press: Birmingham, UK, 1974; Vol. 4, Table 2.2 A.
47. (a) Mosmann, T. J. Immun. Methods 1983, 65, 55.
48. (b) Cole, S. P. C. Cancer Chemother. Pharmacol. 1986, 17, 259.
49. (c) Cole, S. P. C. Cancer Chemother. Pharmacol. 1990, 26, 250.
50. Clearfield, A.; Warner, D. K.; Saldarriaga-Molina, C. H.; Ropal, R.; Bernal, I. Can. J. Chem. 1975, 53, 1622.
51. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; et al. J. Nat. Cancer Inst. 1991, 83, 757. For a general reference for clinical use of cisplatin and Pt-containing drugs, see: Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd ed.; Chabner, B. A., Longo, D. L., Eds.; 1996; Chapter 14, pp 357-378.
52. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; et al. J. Nat. Cancer Inst. 1991, 83, 757. For a general reference for clinical use of cisplatin and Pt-containing drugs, see: Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd ed.; Chabner, B. A., Longo, D. L., Eds.; 1996; Chapter 14, pp 357-378.
53. Messori, L.; Orioli, P.; Banholzer, V.; Pais, I.; Zatta, P. FEBS Lett. 1999, 442, 157.